insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025.

1/5 보강
Cancer innovation 2026 Vol.5(2) p. e70057
Retraction 확인
출처
PubMed DOI PMC

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: BRAF V600E, KRAS mutation, and HER2 amplification
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Precision medicine expanded to patients with BRAF V600E, KRAS mutation, and HER2 amplification. While circulating tumor DNA utility was confirmed for surveillance and guiding rechallenge, its role in real-time treatment adjustment continues to be explored.

Cai Z, Chen F, Jin Y, Wang F

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

This review summarizes landmark advances in colorectal cancer treatment in 2025, characterizing the transition to dynamic precision oncology.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Cai Z, Chen F, et al. (2026). Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025.. Cancer innovation, 5(2), e70057. https://doi.org/10.1002/cai2.70057
MLA Cai Z, et al.. "Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025.." Cancer innovation, vol. 5, no. 2, 2026, pp. e70057.
PMID 41970467
DOI 10.1002/cai2.70057

Abstract

This review summarizes landmark advances in colorectal cancer treatment in 2025, characterizing the transition to dynamic precision oncology. Immunotherapy has revolutionized mismatch repair-deficient or microsatellite instability-high patients, becoming the standard first-line and perioperative regimen. Precision medicine expanded to patients with BRAF V600E, KRAS mutation, and HER2 amplification. While circulating tumor DNA utility was confirmed for surveillance and guiding rechallenge, its role in real-time treatment adjustment continues to be explored.

같은 제1저자의 인용 많은 논문 (5)